PHILADELPHIA, November 11, 2008 - Radiation Therapy Oncology Groups (RTOG) investigators will report recent results from the group’s brain tumor research during six presentations at the at the Society for Neuro-Oncology (SNO) 13th Annual Meeting in Lake Las Vegas, NV November 20 – 23, 2008. RTOG is a National Cancer Institute-funded national clinical trials group and is administered by the American College of Radiology.
An abstract reporting the overall and progression-free survival results of an RTOG randomized trial of radiotherapy with and without chemotherapy for adult low-grade glioma patients was awarded the top score and will be presented in the lead-off session on November 21st by lead author Edward Shaw, MD, of Wake Forest University. Five other presentations of RTOG research will be given during the four-day conference.
“RTOG is an international leader in brain tumor clinical and translational research,” said Walter J. Curran, Jr., MD, the RTOG Group Chair, and the Lawrence W. Davis Professor and chairman of the Department of Radiation Oncology in the Emory School of Medicine and chief medical officer of the Emory Winship Cancer Institute. “The six presentations at this year’s SNO meeting represent results from nine different RTOG clinical trials conducted over the last decade. They include analyses of survival, correlative biomarkers, genetic signatures, and toxicity assessment of multi-modality trials participated in by over 200 academic and community facilities in the United States and Canada.”
The six oral and poster presentations highlight some of the group’s recent brain tumor research. Attached is a complete list the RTOG presentations at the Society for Neuro-Oncology Annual Meeting.
Please visit the RTOG table at the Loews Lake Las Vegas Resort during the SNO meeting. If you would like a copy of an RTOG abstract or to arrange to speak with an RTOG author please contact Sharon Hartson Stine 609-458-5604, email@example.com.
RTOG Presentations at the Society for Neuro-Oncology November 2008
Radiation Therapy (RT) versus RT + Procarbazine, CCNU and Vincristine (PCV) Chemotherapy for Adult Low-Grade Glioma (LGG): Radiation Therapy Oncology Group (RTOG) Protocol 9802.
EG Shaw, M Wang, S Coons, D Brachman, J Buckner, K Stelzer, G Barger, P Brown, M Gilbert, M Mehta.
An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients.
A Chakravarti, M Wang, P Mischel, I Robins, A Guha, M Machtay, W Curran, M Roach, M Mehta, A Dicker.
Predictive Value of hMLH1 after Adjusting for RPA Class in Patients with GBMs Treated on RTOG Protocols.
AJ Choucair, J Moughan, CD Ford, J Hansen, C. Schultz, A Schulsinger, EH Hammond, M Mehta, WJ Curran
Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma (RTOG 0627).
AB Lassman, M Wang, MR Gilbert, K Aldape, H Wagner, DG Brachman, MG Malkin, T Pajak, M Mehta
Toxicity results of RTOG 9813- a Phase III Randomized Study of Radiation Therapy (RT) and Temozolomide (TMZ) versus RT and Nitrosourea (NU) for Anaplastic Astrocytoma (AA) and Mixed Anaplastic Oligoastrocytoma (MAOA).
S Chang, M Wang, G Cairncross, M Gilbert, J-P Bahary, C Dolinskas, K Aldape, A Chakravarti, W Curran, D Schiff, K Jaeckle, G Barger, M Werner-Wasik, D Brachman, R Komaki, R Patel, M Mehta
Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (Mgd), and 60Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma: Results of RTOG 0513 Phase I Dose Escalation Toxicity Analysis.
DG Brachman, LS Ashby, M Wang, T Thomas, B Stea, M Mehta
Director of Public Affairs
American College of Radiology
1891 Preston White Drive
Reston, VA 20191